Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study presented at the ASCO Annual Meeting reported that the epidermal growth factor receptor antibody ABX-EGF showed preliminary efficacy in renal cell cancer patients, with tolerable side effects, while bortezomib demonstrated clinical benefit in a significant proportion of multiple myeloma patients.

This review discusses the role of the hedgehog signaling pathway in hematological cancers and its potential as a therapeutic target; it reports no new clinical findings.

This review examines PAK4 signaling pathways in prostate cancer, Parkinson's disease, and melanogenesis, focusing on the potential role of the PAK4-CREB axis, without reporting new clinical results.

This article reviews strategies for managing the side effects of cytotoxic chemotherapy in primary healthcare settings and reports no new clinical findings.

This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.

This review discusses the role of LGR4 in tumors, highlighting its involvement in cancer progression, metastasis, and chemotherapy resistance, as well as its regulatory effects on tumor stem cell self-renewal and stem cell characteristics, based on multiple recent studies.

This review discusses anti-angiogenic therapy for cancer, highlighting VEGF blockers' effectiveness but also their limitations, such as resistance and adverse effects; it reports no new clinical results.

This study suggests that short-term treatments with specific small molecules may enhance the differentiation potential and stem cell properties of human amniotic fluid stem cells.

This study found that activating the Nrf2 pathway in human mast cells effectively suppresses degranulation and inflammation induced by substance P.

PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This systematic review found that Janus kinase inhibitors have shown beneficial effects for psoriasis and alopecia areata, with promising preliminary results in other skin conditions, though more research is needed to define dosing and safety profiles.

This review discusses the mechanisms and pathways of FGFR signalling and its roles in development, disorders, and therapeutic targeting, but reports no new clinical results.

This review discusses the role of TGF-β signaling in stem cell recruitment and tissue regeneration, indicating that abnormalities in TGF-β activation contribute to various major diseases and suggesting avenues for therapeutic intervention.

This study found that glucose starvation and hypoxia are physiological triggers of ER stress in in vitro differentiated adipocytes, rather than high concentrations of saturated fatty acids, cholesterol, or proinflammatory cytokines.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

This study found that the retinoid all-trans retinoic acid induced a catagen-like stage in human scalp hair follicles, suggesting upregulation of TGF-beta2 as a contributing mechanism.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

This study reported that exposure to 1,763 MHz radiofrequency radiation stimulated hair growth in vitro by inducing insulin-like growth factor-1 expression in cultured human dermal papilla cells.

In this study, re-activating SOX9 in adult epidermal stem cells led to a fate switch towards hair follicle stem cell identity, with altered chromatin dynamics and oncogenic activation, contributing insights into developmental processes and cancer pathways.

This case report details a patient who developed multiple skin cancers within one year of receiving an allogeneic haematopoietic cell transplant for chronic lymphocytic leukaemia.

This study demonstrates that FMOD deficiency in mice alters TGF-β ligand and receptor expression during wound healing stages, leading to delayed wound closure and increased scar size.

Researchers found an RNA transcript that might help control a growth factor linked to tumor development.

This review discusses the molecular mechanisms and therapeutic effectiveness of Janus Kinase Inhibitors for inflammatory skin diseases, suggesting these inhibitors have a rapid onset and favorable safety profile compared to conventional treatments.

This material provides comprehensive information about actinic keratosis, highlighting its potential outcomes, risk factors, clinical features, diagnosis, and treatment considerations for medical specialists.

This study provides a comprehensive overview of actinic keratosis, highlighting its potential to progress to squamous cell carcinoma and noting that routine treatment poses a significant burden on healthcare providers.

This study found that PDGF-BB affects human melanocytes differently depending on their differentiation stage, stimulating melanoblast proliferation but inhibiting melanocyte proliferation while promoting their differentiation.

This article discusses the interest in folic acid antagonists for leukemia treatment, noting their potential mechanism of interfering with cellular growth, but reports no new clinical results.

This review discusses the advancements in intraoperative stem cell therapies and highlights their potential to improve hair regrowth, but it reports no new clinical results.

In this study, researchers demonstrated that in a mouse model, the stimulation of mammary tumor growth due to progesterone is primarily caused by its metabolite, 5αP, not progesterone itself.